A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours

Richard Wilson, P. Hari Dass, Sandra Van Schaeybroeck, Elena Elez, A Quinton, R. Jones, Jennifer Houlden, Linda Collins, C Roberts, Sharon Love, Mark Lawler, Federica Di Nicolantonio, Margaret Grayson, alberto Bardelli, Pierre Laurent=puig, Tim Maughan, Josef Tabernero, Marc Peeters, Mark Middleton, Christian Rolfo

Research output: Contribution to journalMeeting abstract

Original languageEnglish
Pages (from-to)e140-e141
JournalEuropean Journal of Cancer
Volume103
Issue numberSuppl 1
Publication statusPublished - Nov 2018

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Neoplasms
Creatinine
Phosphotransferases
Fatigue
Colorectal Neoplasms
Pharmacokinetics
Safety
crizotinib
MEK162
Exanthema
Nausea
Diarrhea
Appointments and Schedules
Biopsy
Skin
Survival

Cite this

Wilson, Richard ; Dass, P. Hari ; Van Schaeybroeck, Sandra ; Elez, Elena ; Quinton, A ; Jones, R. ; Houlden, Jennifer ; Collins, Linda ; Roberts, C ; Love, Sharon ; Lawler, Mark ; Di Nicolantonio, Federica ; Grayson, Margaret ; Bardelli, alberto ; Laurent=puig, Pierre ; Maughan, Tim ; Tabernero, Josef ; Peeters, Marc ; Middleton, Mark ; Rolfo, Christian. / A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours. In: European Journal of Cancer. 2018 ; Vol. 103, No. Suppl 1. pp. e140-e141.
@article{149f2ca3f6a64f5dac4e04b7acc6616b,
title = "A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours",
author = "Richard Wilson and Dass, {P. Hari} and {Van Schaeybroeck}, Sandra and Elena Elez and A Quinton and R. Jones and Jennifer Houlden and Linda Collins and C Roberts and Sharon Love and Mark Lawler and {Di Nicolantonio}, Federica and Margaret Grayson and alberto Bardelli and Pierre Laurent=puig and Tim Maughan and Josef Tabernero and Marc Peeters and Mark Middleton and Christian Rolfo",
year = "2018",
month = "11",
language = "English",
volume = "103",
pages = "e140--e141",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier",
number = "Suppl 1",

}

Wilson, R, Dass, PH, Van Schaeybroeck, S, Elez, E, Quinton, A, Jones, R, Houlden, J, Collins, L, Roberts, C, Love, S, Lawler, M, Di Nicolantonio, F, Grayson, M, Bardelli, A, Laurent=puig, P, Maughan, T, Tabernero, J, Peeters, M, Middleton, M & Rolfo, C 2018, 'A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours', European Journal of Cancer, vol. 103, no. Suppl 1, pp. e140-e141.

A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours. / Wilson, Richard; Dass, P. Hari; Van Schaeybroeck, Sandra; Elez, Elena; Quinton, A; Jones, R.; Houlden, Jennifer; Collins, Linda; Roberts, C; Love, Sharon; Lawler, Mark; Di Nicolantonio, Federica; Grayson, Margaret; Bardelli, alberto; Laurent=puig, Pierre; Maughan, Tim; Tabernero, Josef; Peeters, Marc; Middleton, Mark; Rolfo, Christian.

In: European Journal of Cancer, Vol. 103, No. Suppl 1, 11.2018, p. e140-e141.

Research output: Contribution to journalMeeting abstract

TY - JOUR

T1 - A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours

AU - Wilson, Richard

AU - Dass, P. Hari

AU - Van Schaeybroeck, Sandra

AU - Elez, Elena

AU - Quinton, A

AU - Jones, R.

AU - Houlden, Jennifer

AU - Collins, Linda

AU - Roberts, C

AU - Love, Sharon

AU - Lawler, Mark

AU - Di Nicolantonio, Federica

AU - Grayson, Margaret

AU - Bardelli, alberto

AU - Laurent=puig, Pierre

AU - Maughan, Tim

AU - Tabernero, Josef

AU - Peeters, Marc

AU - Middleton, Mark

AU - Rolfo, Christian

PY - 2018/11

Y1 - 2018/11

M3 - Meeting abstract

VL - 103

SP - e140-e141

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - Suppl 1

ER -